RTP Mobile Logo

Interview with Richard S Finn, MD

Track 1: Effects of locoregional therapy on underlying liver function in patients with hepatocellular carcinoma (HCC)
Track 2: Barcelona Clinic Liver Cancer staging system and treatment strategy
Track 3: Case: A 68-year-old man with chronic hepatitis C and thrombocytopenia undergoes a liver transplant for multifocal HCC
Track 4: Risk of recurrence in patients undergoing liver transplantation for HCC
Track 5: Use of sorafenib in patients who develop disease recurrence after a liver transplant
Track 6: Risks associated with administering immune checkpoint inhibitors to patients who have undergone a liver transplant
Track 7: REFLECT (Study 304): A Phase III trial of lenvatinib versus sorafenib as first-line treatment for unresectable HCC
Track 8: Design and eligibility criteria for the REFLECT study
Track 9: Activity and side-effect profile of lenvatinib versus sorafenib
Track 10: Clinical implications of the REFLECT trial results
Track 11: Comparison of selective internal radiation therapy (SIRT) to sorafenib for locally advanced HCC
Track 12: Results of the Phase III RESORCE trial evaluating regorafenib for patients with HCC and disease progression after sorafenib
Track 13: Activity of nivolumab as second-line therapy for patients with HCC
Track 14: Selection of regorafenib versus nivolumab as treatment in the second-line setting
Track 15: Predictors of benefit with checkpoint inhibitors in HCC
Track 16: Emerging data on the efficacy of anti-PD-1/PD-L1 and anti-CTLA-4 combinations
Track 17: Management of hepatic toxicities in patients receiving checkpoint inhibitors
Track 18: Biologic rationale for and ongoing investigation of the combination of checkpoint inhibitors and anti-angiogenic agents
Track 19: Results of the Phase III CELESTIAL trial of cabozantinib versus placebo for patients with advanced HCC who have previously received sorafenib
Track 20: Improvement in overall survival with ramucirumab versus placebo as second-line treatment for patients with advanced HCC and elevated baseline alpha-fetoprotein (AFP)
Track 21: Selection and sequencing of therapy for patients with HCC
Track 22: Role of checkpoint inhibitors in the treatment algorithm for HCC
Track 23: Case: A 70-year-old man with metastatic HCC to the lung and a history of hepatitis B achieves a dramatic response to nivolumab
Track 24: Ongoing Phase III evaluation of checkpoint inhibitors for HCC

Interview with Andrew X Zhu, MD, PhD

Track 1: Epidemiology and etiology of HCC
Track 2: Selection of patients for locoregional treatment
Track 3: Available locoregional therapies for HCC
Track 4: Side effects associated with locoregional therapies
Track 5: Tumor microenvironment in HCC and potential therapeutic role of anti-angiogenic agents and immunotherapies
Track 6: Perspective on the results of the RESORCE study evaluating regorafenib after disease progression on sorafenib
Track 7: Dose modifications and side effects associated with regorafenib
Track 8: Critical evaluation of the CELESTIAL trial efficacy and tolerability results
Track 9: Potential role of cabozantinib in the management of HCC
Track 10: Results of the REACH-2 study of ramucirumab as second-line treatment for patients with advanced HCC and elevated AFP after first-line sorafenib
Track 11: Emerging data on a correlation between high AFP and response to ramucirumab
Track 12: Efficacy and tolerability of lenvatinib versus sorafenib as first-line therapy in the Phase III REFLECT trial (Study 304)
Track 13: Activity of checkpoint inhibitors in patients with HCC
Track 14: Combination immunotherapy approaches under investigation for HCC
Track 15: Case: A 62-year-old man with metastatic HCC achieves a partial response to nivolumab/ipilimumab on the CheckMate 040 study
Track 16: Case: A 72-year-old woman receives nivolumab as second-line therapy for NASH-related HCC
Track 17: Case: A 49-year-old man with a history of hepatitis B receives lenvatinib in combination with nivolumab for multifocal HCC
Track 18: Case: A 64-year-old woman with NASH-related HCC receives regorafenib after disease progression on sorafenib
Track 19: Perspective on the use of checkpoint inhibitors for liver transplant recipients
Richard S Finn, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Dumont-UCLA Liver Cancer Center
Geffen School of Medicine at UCLA
Los Angeles, California

Andrew X Zhu, MD, PhD
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida